More people survive cancer today than at any point in history. An estimated 18.6 million cancer survivors are living in the United States right now, and the overall five-year survival rate for all cancers combined has climbed from about 50% in 1975 to nearly 74% in recent years. That means roughly three out of four people diagnosed with cancer today will be alive five years later.
Overall Survival Has Risen Dramatically
In the mid-1970s, a cancer diagnosis was close to a coin flip: about 49.8% of people survived at least five years. By 2018 (the most recent year with complete long-term data), that number reached 73.6%. That’s a roughly 24-percentage-point improvement across all cancer types combined, driven by better screening, earlier detection, and treatments that didn’t exist a generation ago.
Five-year survival is the standard benchmark in oncology, but it doesn’t mean someone is only alive for five years. It measures the percentage of people still living five years after diagnosis compared to the general population. Many of those people go on to live full, normal lifespans.
Survival Varies Widely by Cancer Type
The phrase “beating cancer” means very different things depending on which cancer you’re talking about. Some types are almost always survivable when caught in time. Others remain extremely difficult to treat. The most recent five-year survival rates for the four most common cancers in the U.S. illustrate this range:
- Prostate: 98.2%
- Breast: 91.9%
- Colorectal: 65.4%
- Lung: 29.5%
Prostate and breast cancer survivors make up a huge share of the 18.6 million people living after a cancer diagnosis. Their high survival rates pull the overall average up considerably. Lung cancer, despite being one of the most commonly diagnosed cancers, has a much lower survival rate because it’s often found at an advanced stage and is harder to treat once it has spread.
Stage at Diagnosis Changes Everything
Perhaps the single biggest factor in whether someone beats cancer is how early it’s found. Cancers caught while still localized (confined to the organ where they started) have dramatically better outcomes than those diagnosed after spreading to distant parts of the body. For many common cancers, localized-stage survival rates are above 90%, while metastatic (stage 4) survival drops to single digits or low double digits.
This is why screening programs for breast, colorectal, cervical, and lung cancer exist. People from lower-income backgrounds or medically underserved communities are more likely to be diagnosed at later stages, when treatment is less effective. Research from the National Cancer Institute shows that socioeconomic status, even more than race or ethnicity, predicts a person’s access to early diagnosis and ultimately their likelihood of survival.
Children Now Survive at High Rates
Childhood cancer survival is one of the clearest success stories in modern medicine. In the mid-1970s, 58% of children under 14 and 68% of adolescents aged 15 to 19 survived at least five years. Today, those numbers have climbed to roughly 84% to 88% across all pediatric age groups. Children aged 1 to 4 have the highest rate at 87.8%, and adolescents are close behind at 87.3%.
This improvement came largely from advances in chemotherapy combinations, better supportive care during treatment, and clinical trials that enrolled a high proportion of pediatric patients. Childhood leukemia, once almost universally fatal, now has five-year survival rates above 90% for the most common subtypes.
Newer Treatments Are Shifting the Numbers
For cancers that were historically almost untreatable, newer approaches are making a measurable difference. Advanced lung cancer is a striking example. When a UCLA-led study began tracking patients with advanced non-small cell lung cancer in 2012, the average five-year survival rate was just 5.5%. After treatment with immunotherapy, more than 15% of participants survived at least five years. Among patients whose tumors had a specific protein marker that makes immunotherapy more effective, 25% to 30% were alive at the five-year mark.
Those numbers might sound modest compared to prostate or breast cancer survival, but they represent a threefold to fivefold improvement for a disease that was previously a near-certain death sentence at the advanced stage. Similar gains have been seen in advanced melanoma and certain blood cancers.
What “Beating Cancer” Actually Means
The word “cured” has a specific meaning in oncology: no detectable traces of cancer remain, and it never comes back. Doctors are cautious with this word. More commonly, they use “remission,” which means the signs and symptoms of cancer have been reduced. Complete remission means all detectable cancer is gone. If someone stays in complete remission for five years or more, many oncologists will consider them cured.
In practice, this means the 18.6 million cancer survivors in the U.S. are a mix of people: some are fully cured and decades past their diagnosis, some are in remission and being monitored, and some are living with cancer as a managed chronic condition. The growing number of survivors reflects not just better cures but also people living longer with cancers that would have killed them quickly in previous decades.
Who Is More and Less Likely to Survive
Survival statistics are averages, and they mask significant disparities. Income, education, insurance status, and where someone lives all influence their odds. People from lower socioeconomic backgrounds face higher cancer mortality, largely because they’re diagnosed later, have less access to specialized treatment centers, and face more barriers to completing treatment. These gaps persist even when comparing people with the same type and stage of cancer.
Geography matters too. Access to comprehensive cancer centers, which offer clinical trials and the latest treatments, is concentrated in urban areas. Rural patients often travel long distances for care or receive treatment at facilities with fewer resources. The survival rates cited above represent national averages, and individual outcomes can vary substantially depending on these factors.